Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of November 2020. The report serves as a transaction notification regarding a sale of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for GSK Plc. It reports solely on a specific equity transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Sale.
- Volume: 21,828 shares.
- Price: £13.461 per share.
- Transaction Date: November 3, 2020.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not provide comparative financial data or material changes to the company's operational performance versus prior periods. The only reported change is the reduction in shareholding by the specific individual identified below.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a regulatory disclosure of a transaction executed by:
- Name: Ms. D. Waterhouse.
- Position: CEO of ViiV Healthcare.
Investor Verification Points
- Verify the total shareholding of Ms. D. Waterhouse post-transaction to assess remaining exposure.
- Confirm the transaction price (£13.461) against the market price of GSK shares on November 3, 2020.
- Note that this filing does not reflect the financial health or performance of GSK Plc or ViiV Healthcare; refer to Form 20-F for financial results.